Pamorelin (Triptorelin)

Pamorelin is a GnRH agonist that modulates the hormonal axis in several endocrine‑related conditions.

• Prostate cancer: provides androgen suppression to slow tumor progression.
• Endometriosis: induces hypo‑estrogenic state to reduce pelvic pain and lesion growth.
• Uterine fibroids: creates a low‑estrogen environment that can shrink fibroid size and lessen bleeding.
• Assisted reproductive technology (ART) protocols: controls ovarian stimulation timing for improved cycle management.

• Triptorelin is a synthetic decapeptide that binds with high affinity to pituitary GnRH receptors. Continuous stimulation leads to receptor desensitisation and down‑regulation, markedly reducing the release of luteinising hormone (LH) and follicle‑stimulating hormone (FSH). The consequent decline in circulating sex steroids (testosterone and estrogen) underpins its therapeutic effects in hormone‑sensitive diseases.

Adverse reactions to Triptorelin vary with treatment duration and patient characteristics.

Common Side Effects

• Hot flashes
• Headache
• Injection site pain or erythema
• Fatigue
• Nausea
• Decreased libido

Serious or Rare Side Effects

• Severe allergic reaction (anaphylaxis)
• Cardiovascular events such as myocardial infarction
• Bone mineral density loss leading to osteoporosis
• Severe hepatic dysfunction
• Acute adrenal insufficiency
• Pituitary apoplexy (very rare)

When prescribing Triptorelin, clinicians should consider several safety aspects.

• Cardiac monitoring: patients with known cardiovascular disease should be evaluated regularly.
• Bone health: assess risk of osteoporosis, especially with long‑term use.
• Hormone‑dependent tumor surveillance: monitor for disease progression.
• Pregnancy avoidance: effective contraception is required for women of child‑bearing potential.
• Drug interactions: review concomitant medications that affect hormone levels.
• Store at ambient temperature: keep in original packaging, protect from moisture and light.

Triptilelin interacts with several drug classes, requiring attention to avoid reduced efficacy or heightened toxicity.

Major Interactions (Avoid)

• Combined hormonal contraceptives: may blunt the intended hypo‑estrogenic effect.
• Anti‑androgen therapy : interfer ").

Moderate "). -  -  -  -  -